pbm glp-1 news BREAKING GLP1 3/4/26: Slashed Prices, saving lives AND reform?! GLP-1 Pricing & PBM Revenue

By interrupting cytokine synthesis and cytokine processing, caudatin interrupts both upstream signaling pathways and downstream effector mechanisms of mast cell-mediated inflammation, which favors its characterization as a therapeutic candidate for pathologies in which excessive inflammatory responses occur, such as in the case of severe acute respiratory distress syndrome due to COVID-19 (Figure 3A)

EMBO Reports , 21 (8), e51069

FDA approved : For the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension

The Hims announcement came after the Danish pharmaceutical company shared a bleak market outlook

Hashemi, Z